X
Search
X

Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

FDA Approves Jevtana for Prostate Cancer Subset

Jevtana (cabazitaxel) was granted approval by the Food and Drug Administration (FDA) for the treatment of men with metastatic castration-resistant prostate cancer who previously received a docetaxel-containing regimen.

Read more.

source: CURE Magazine